Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

医学 缬沙坦 雷米普利 内科学 危险系数 临床终点 心力衰竭 心脏病学 心肌梗塞 螺内酯 沙库比林 中止 血管紧张素转换酶抑制剂 依那普利 依瓦布拉定 置信区间 临床试验 射血分数 血压 血管紧张素转换酶 心率
作者
Morten Schou,Brian Claggett,Zi Michael Miao,Alberto Fernández,Gerasimos Filippatos,Christopher B. Granger,Karola Jering,Aldo P. Maggioni,Finnian R. Mc Causland,Julio Núñez,Jean‐Lucien Rouleau,Freny Vaghaiwalla Mody,Peter van der Meer,Dragoş Vinereanu,Martina M. McGrath,Yinong Zhou,Douglas L. Mann,Scott D. Solomon,Philippe Gabríel Steg,Eugene Braunwald,John J.V. McMurray,Marc A. Pfeffer,Lars Køber
出处
期刊:European Journal of Heart Failure [Elsevier BV]
卷期号:26 (1): 130-139 被引量:2
标识
DOI:10.1002/ejhf.3079
摘要

Abstract Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high‐risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. Methods and results Patients ( n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI ( p > 0.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR] MRA 0.96, 95% confidence interval [CI] 0.77–1.19 and HR MRA– 0.87, 95% CI 0.71–1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator‐reported endpoints were evaluated ( p = 0.61 for interaction). Conclusions Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post‐MI setting in patients with LVSD and/or congestion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
rhei完成签到,获得积分10
1秒前
多多俊颐宝贝完成签到 ,获得积分10
3秒前
4秒前
小丸子发布了新的文献求助10
4秒前
小任性完成签到,获得积分20
5秒前
汪海洋关注了科研通微信公众号
6秒前
多多俊颐宝贝关注了科研通微信公众号
7秒前
陈强强发布了新的文献求助10
8秒前
ASH完成签到 ,获得积分10
8秒前
大喵发布了新的文献求助10
9秒前
Hale完成签到,获得积分0
9秒前
Steven发布了新的文献求助30
10秒前
科研通AI2S应助黑色土豆采纳,获得10
10秒前
猪猪hero应助黑色土豆采纳,获得10
10秒前
11秒前
充电宝应助三年H采纳,获得10
13秒前
17秒前
21秒前
绿泡泡发布了新的文献求助10
22秒前
夏佳泽完成签到 ,获得积分10
22秒前
zhxq完成签到,获得积分10
23秒前
23秒前
Rondab应助小丸子采纳,获得30
24秒前
25秒前
红枫没有微雨怜完成签到 ,获得积分10
26秒前
十八完成签到,获得积分10
26秒前
三年H发布了新的文献求助10
27秒前
27秒前
王杨发布了新的文献求助10
28秒前
归尘发布了新的文献求助10
30秒前
汪海洋发布了新的文献求助10
32秒前
陈槊诸完成签到 ,获得积分10
34秒前
QDU应助绿泡泡采纳,获得10
36秒前
MXene发布了新的文献求助10
37秒前
40秒前
liziqi发布了新的文献求助10
45秒前
46秒前
46秒前
mutongchen关注了科研通微信公众号
47秒前
Damon完成签到 ,获得积分10
48秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531910
关于积分的说明 11255394
捐赠科研通 3270563
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809190